Clinical trials: Ovarian Disease
Ovarian Cancer, mRNA Vaccine
A Single-Arm, Open-Label, Prospective Study Evaluating the Safety, Tolerability, and Immunogenicity of the NeoOVSV Vaccine in Patients With Ovarian Cancer After Surgery
This is a Phase I, single-arm, open-label, prospective, non-randomized, single-center dose-escalation study. The study will evaluate the safety, tolerability, and preliminary activity of the NeoOVSV mRNA-lipid nanoparticle…
- Trial name
- NeoOVSV (NCT07724106)
- Testing
- Low Dose, middle dose, high dose
- Where
- China
- Volunteers
- 9 people
- Sponsor
- West China Hospital
Healthy
Measurement of the Folate Receptor in Blood
The folate receptor (FR) is a cell marker that is over expressed on the cell surface of certain cancers, this occurs most frequently in ovarian cancers.
- Trial name
- NCT00838747
- Where
- United Kingdom
- Volunteers
- 7 people, healthy volunteers welcome
- Sponsor
- Royal Marsden NHS Foundation Trust
Sexual Dysfunctions, Psychological, Uterine Cervical Neoplasms
A Randomized Controlled Trial of an Online Support Group for Sexual Distress Due to Gynecologic Cancer
There is a high prevalence of sexual and body image problems among women treated for gynecologic cancer, which can lead to considerable distress.
- Conditions
- Sexual Dysfunctions, Psychological, Uterine Cervical Neoplasms, Ovarian Neoplasms, Uterine Neoplasms
- Trial name
- NCT01654458
- Testing
- GyneGals Support Group
- Where
- 7 sites in United States, Canada
- Volunteers
- 398 people
- Sponsor
- Women's College Hospital
Ovarian Cancer, Endometrial Cancer
Weekly Paclitaxel/Carboplatin With Neupogen in Gynaecological Cancers
Rationale: The administration of prophylactic G-CSF may reduce the toxicity of a weekly paclitaxel/carboplatin regimen in gynaecological cancers.
- Conditions
- Ovarian Cancer, Endometrial Cancer, Uterine Cervical Cancer
- Trial name
- NCT01523678
- Testing
- Filgrastim, Paclitaxel, Carboplatin
- Where
- 17 sites in Belgium
- Volunteers
- 108 people
- Sponsor
- Belgian Gynaecological Oncology Group
Cancer
SC-004 Alone or With ABBV-181 in Subjects With Epithelial Ovarian, Fallopian Tube, Primary Peritoneal and Endometrial Cancers
This is a two-part study consisting of Part A (dose regimen finding) followed by Part B (dose expansion). Part A (dose regimen finding) will allow definition of the maximum tolerated dose (MTD) through dose escalation and…
- Trial name
- NCT03138408
- Testing
- SC-004, ABBV-181
- Where
- 12 sites in United States
- Volunteers
- 24 people
- Sponsor
- AbbVie
Polycystic Ovary Syndrome
Impact of Metformin in Teens With Polycystic Ovary Syndrome (PCOS) on Oral Contraceptive Therapy
Oral contraceptives are known to improve menstrual cycles and symptoms in PCOS, however may increase cholesterol. Metformin, a drug to improve insulin resistance, may benefit metabolic state.
- Trial name
- NCT00283816
- Testing
- Metformin, Oral Contraceptive Pill, Lifestyle Management Program
- Where
- United States
- Volunteers
- 36 people, healthy volunteers welcome
- Sponsor
- University of Rochester
Metastatic Breast Cancer, Recurrent Ovarian Carcinoma
Ribociclib&Belinostat In Patients w Metastatic Triple Neg Breast Cancer & Recurrent Ovarian Cancer w Response Prediction By Genomics
This is an open-label, multi-center, phase I study designed to assess the maximum tolerated dose of ribociclib and belinostat in combination.
- Trial name
- CHARGE (NCT04315233)
- Testing
- Ribociclib, Belinostat
- Where
- 2 sites in United States
- Volunteers
- 12 people
- Sponsor
- University of Utah
Ovarian Cancer
TPIV200/huFR-1 (A Multi-Epitope Anti-Folate Receptor Vaccine) Plus Anti-PD-L1 MEDI4736 (Durvalumab) in Patients With Platinum Resistant Ovarian Cancer
This is a Phase 2 clinical trial, which tests two investigational drugs: TPIV200/huFR-1 (also called TPIV200), which is a vaccine consisting of proteins from the folate receptor alpha mixed with GM-CSF, and durvalumab (MEDI4736)…
- Trial name
- NCT02764333
- Testing
- TPIV200, Durvalumab
- Where
- 5 sites in United States
- Volunteers
- 29 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Malignancy, Non-hodgkin Lymphoma
A Phase 1/2 Study of CYT-0851 in B-Cell Malignancies and Advanced Solid Tumors
This clinical trial is an interventional, active-treatment, open-label, multi-center, Phase 1/2 study. The study objectives are to assess the safety, tolerability and pharmacokinetics (PK) of CYT-0851 in patients with…
- Conditions
- Malignancy, Non-hodgkin Lymphoma, Multiple Myeloma, Breast Cancer
- Trial name
- NCT03997968
- Testing
- CYT-0851, CYT-0851 in combination with gemcitabine, CYT-0851 in combination with capecitabine
- Where
- 16 sites in United States
- Volunteers
- 169 people
- Sponsor
- Cyteir Therapeutics, Inc.
Premature Ovarian Insufficiency, Bone Diseases, Metabolic
The Bone Metabolism Characteristics of Premature Ovarian Insufficiency
Explore the bone metabolism characteristics of premature ovarian insufficiency.
- Conditions
- Premature Ovarian Insufficiency, Bone Diseases, Metabolic, Bone Mineral Density
- Trial name
- POI (NCT06339489)
- Testing
- Testing the serum levels of bone metabolic markers
- Where
- China
- Volunteers
- 60 people
- Sponsor
- Shi Yun
PCOS
Correction of Vitamin D Deficiency and Its Effect on Ovulation Induction in Women With PCOS (VIDEO): A Feasibility RCT
Recently, a special emphasis has recently been directed to the potential role of vitamin D and some regulatory peptides (e.g. adipokines and follistatin) and their associated metabolic roles and genetic factors in the development…
- Trial name
- PCOSD (NCT02656121)
- Testing
- Vitamin D, Ovulatory Agent
- Where
- Egypt
- Volunteers
- 300 people, healthy volunteers welcome
- Sponsor
- Ain Shams University
Ovarian Cancer, Clinical Marker
The Clinical Markers for PARP Inhibitors-related Efficacy in Ovarian Cancer
Epithelial ovarian cancer (EOC) is the most lethal gynecological malignancy. PARP inhibitors(PARPi) are an important progress in EOC treatment.
- Conditions
- Ovarian Cancer, Clinical Marker, PARP Inhibitor
- Trial name
- ROMP (NCT04582552)
- Testing
- PARP inhibitors
- Where
- China
- Volunteers
- 60 people
- Sponsor
- Xiaoxiang Chen
Ovarian Cancer, Ovarian Neoplasms
A Trial of Vigil for Participants With Ovarian Cancer
The goal of this clinical trial is to compare participants with ovarian, fallopian tube or primary peritoneal cancer when treated with investigational product (Vigil) compared to placebo.
- Trial name
- VITAL (NCT02346747)
- Testing
- Vigil
- Where
- 26 sites in United States
- Volunteers
- 92 people
- Sponsor
- Gradalis, Inc.
HNSCC, ESCC
A Phase 1 Study of NRM-823 in Participants With Locally Advanced or Metastatic Refractory Solid Tumors
This study is being done to find out of NRM-823 is safe and can treat participants with locally advanced or metastatic solid tumors.
- Conditions
- HNSCC, ESCC, Esophageal Adenocarcinoma, Gastric Adenocarcinoma
- Trial name
- NCT07182149
- Testing
- NRM-823
- Where
- 18 sites in United States
- Volunteers
- 150 people
- Sponsor
- Normunity AccelCo, Inc.
Polycystic Ovary Syndrome, Obesity
The Effect of a Liraglutide on IVF in Obese PCOS
The aim of this study was to evaluate the impact of low dose liraglutide in combination with metformin compared to metformin alone on IVF pregnancy rate (PR) and cumulatively PR (IVF and spontaneous) in infertile obese women with…
- Conditions
- Polycystic Ovary Syndrome, Obesity, Infertility, Female
- Trial name
- NCT03353948
- Testing
- MET, COMBI
- Volunteers
- 30 people
- Sponsor
- University Medical Centre Ljubljana
Recurrent Ovarian Carcinoma
Dalpiciclib Combined With Letrozole in HR+/HER2 - Gynecologic Solid Tumors
This is a prospective, single-arm, single-center registry study to investigate 6-month progression-free survival with Dalpiciclib, a CDK4/6 kinase inhibitor, plus letrozole in patients with unresectable refractory or resistant…
- Trial name
- NCT06243185
- Testing
- Dalpiciclib plus letrozole
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Fengzhi Feng
Fallopian Tube Cancer, Ovarian Cancer
Monoclonal Antibody Vaccine Therapy in Treating Patients With Ovarian Epithelial, Fallopian Tube, or Peritoneal Cancer
RATIONALE: Vaccines made from monoclonal antibodies combined with tumor cells may make the body build an immune response to kill tumor cells.
- Conditions
- Fallopian Tube Cancer, Ovarian Cancer, Primary Peritoneal Cavity Cancer
- Trial name
- NCT00058435
- Testing
- abagovomab
- Where
- United States
- Sponsor
- Memorial Sloan Kettering Cancer Center
Ovarian Cancer, Fallopian Tube
A Phase I Study of WT1 or NY-ESO-1 Vaccine and Nivolumab For Recurrent Ovarian Cancer
The purpose of this study is to test the safety of a combination of an investigational WT1 vaccine and another drug called nivolumab. This is the first time that the WT1 vaccine and nivolumab are being used in combination.
- Conditions
- Ovarian Cancer, Fallopian Tube, Primary Peritoneal Cancer, Recurrent Ovarian Cancer
- Trial name
- NCT02737787
- Testing
- WT1 Vaccine, Nivolumab, NY-ESO-1 Vaccine
- Where
- 7 sites in United States
- Volunteers
- 11 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Polycystic Ovary Syndrome, Obesity
Effects of GLP-1RAs on Reproductive Outcomes in PCOS and Obesity
The goal of this clinical trial is to examine whether benalutide combined with metformin and healthy lifestyle education in women with PCOS and obesity prior to fertility treatment improves live birth rate and other reproductive…
- Conditions
- Polycystic Ovary Syndrome, Obesity, Infertility, Female
- Trial name
- NCT06775093
- Testing
- GLP-1 receptor agonist, Metformin, healthy lifestyle education
- Where
- China
- Volunteers
- 392 people
- Sponsor
- Peking University Third Hospital
Female Infertility Due to Diminished Ovarian Reserve
Human Growth Hormone Pre-treatment for 6 Weeks Prior to Ovulation Induction for IVF
Synthetic human growth hormone (HGH) has been available for more than a decade for specific indication in children and adults. Past Randomized Control Trials (RCT)s of HGH (under off-label use) for improving ovarian function have…
- Trial name
- NCT02179255
- Testing
- Human Growth Hormone, Follicle Stimulating Hormone
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Center for Human Reproduction
The first 5,000 results can be paged through. Add a filter or change the sort order to reach the rest.